


DIGNITANA

Clinically superior scalp cooling

FEBRUARY 17 • 2022

**Continued US growth
fuels 25 percent
revenue increase**



Q4 21

YEAR END REPORT

Continued US growth fuels 25 percent revenue increase

Financial highlights Q4 2021

- Net sales amounted to 16.2 MSEK (12.9), an increase of 25 percent over the same period 2020.
- Operating result amounted to -11.4 MSEK (-19.7).
- Net result after financial items amounted to -11.8 MSEK (-20.8).
- Earnings per share were -0,18 SEK (-0,37).
- Cash Balance amounted to 14.5 MSEK (78.8).
- Average Daily Treatment Revenue (ADTR)* was 155 TSEK (130), an increase of 19 percent over the same period in 2020.

Financial highlights January – December 2021

- Net sales amounted to 57.1 MSEK (46.6), an increase of 22 percent over the same period 2020.
- Operating result amounted to -41.6 MSEK (-50.7).
- Net result after financial items amounted to -43.1 MSEK (-53.0).
- Earnings per share were -0,66 SEK (-0,96).
- Cash Balance amounted to 14.5 MSEK (78.8).
- Average Daily Treatment Revenue (ADTR)* was 147 TSEK (120), an increase of 22 percent over the same period in 2020.
- Impacting operating results, the Company has taken non-recurring cost of 9.6 MSEK in 2021 related to Quality System and Market Access improvements.

Significant events during the period

- Dignitana announced a decision from Medicare enabling reimbursement to cancer centers providing DigniCap to chemotherapy patients in the US effective 1 January 2022.
- In December Dignitana CEO William Cronin notified the Board of Directors of his intention to resign as CEO in May.

Business highlights during the period

- Five DigniCap patients were recognized as DigniCap Dignitaries during Breast Cancer Awareness month and interviewed in weekly Facebook Live broadcasts in October.
- Dignitana CEO William Cronin spoke at Erik Penser Bank's Bolagsdag in November 2021, addressing the Company's overall growth strategy and the significance of recent reimbursement initiatives in the US, including the January 2022 Medicare classification for scalp cooling.
- Dignitana exhibited at the San Antonio Breast Cancer Symposium in December.

Significant events after the period

- The Board appointed Catarina Mård Löwenadler as the new CEO of Dignitana. She has extensive experience from leading positions in both MedTech and sales and will take over as CEO after the Annual General Meeting in May.
- The company had previously announced that Magnus Blixt would become CEO, however he chose not to take the role due to personal reasons.
- The company named Alf Christensson as Interim CFO and he will assume the role 1 March 2022.

Business highlights after the period

- Dignitana CEO William Cronin will address the Stockholm Corporate Finance Life Science Capital Markets Days on 9 March, providing an update on the company's strategic growth and discuss current reimbursement initiatives.
- Continuing the partnership with Susan G Komen®, in March Dignitana will sponsor the More than Pink Walk in Orlando, Florida.

"During these challenging times our company has continued to grow and adapt to the unique and generational challenges we face."

William Cronin, CEO Dignitana AB

Key Figures

DIGNITANA GROUP	Q4 2021	Q4 2020	Full year 2021	Full year 2020
Net sales, TSEK	16 213	12 928	57 073	46 629
Total revenues, TSEK	17 322	13 006	62 376	49 956
Net profit after financial items, TSEK	-11 836	-20 821	-43 076	-52 963
Cash and bank balances, TSEK	14 501	78 770	14 501	78 770
Earnings per share before and after dilution, SEK	-0,18	-0,37	-0,66	-0,96
Average Daily Treatment revenue, TSEK	155	130	147	120

* ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.

DIGNITANA AB IS A SWEDISH MEDICAL TECHNOLOGY COMPANY THAT PRODUCES AND MARKETS THE DIGNICAP SCALP COOLING SYSTEM TO MINIMIZE HAIR LOSS DURING CHEMOTHERAPY AND IMPROVE WELL-BEING AND QUALITY OF LIFE FOR CANCER PATIENTS.

Continued US growth fuels 25 percent revenue increase

As we review the Company's accomplishments over the past year, I am especially pleased that our revenue growth has continued each quarter of the year, despite continuing obstacles from the ongoing pandemic which very much impacted access to our customers. We continue to grow as a result of increasing customer awareness of scalp cooling, but also the unwavering commitment of our team to continue delivering results in a very difficult business climate. While the recent wave of Omicron Covid cases seems to be abating, the healthcare field is still very much struggling under the weight of the pandemic. In addition to limited access, like many businesses, we have also been impacted by supply chain issues and a changing labor market. During these challenging times our company has continued to grow and adapt to the unique and generational challenges we face.

In our primary U.S. market there were 386 DigniCap Delta devices in a total of 328 locations at the close of the year. While we continue to sign new high-value contracts, we are increasingly focused on optimizing utilization of devices with current customers. It is worth noting that although DigniCap clearance was expanded in 2019 beyond women with breast cancer to include use by men and women with any solid tumor, the vast majority of our patients are still female breast cancer patients. This leaves tremendous opportunity to develop scalp cooling usage with other regimens and diagnoses and to broaden the circle of physicians who recommend scalp cooling to their patients.

I am happy to report that we reached another milestone reached this quarter as the legacy C3 product has now been completely removed from the U.S. market. The DigniCap Delta device is far more suited to the demands of the U.S. healthcare market and by removing the final C3 units we can more fully concentrate our efforts on our core DigniCap Delta product.

The fourth quarter also generated another record for our all-important Average Daily Treatment Revenue (ADTR) metric. Our 155 TSEK number represented a 19 percent increase over the same period in 2020. Again, with the pandemic coming back to life in the fourth quarter, we are very pleased with this performance.

2021 saw significant progress on the reimbursement front with the introduction of two CPT® codes for scalp cooling in July and a successful appeal to Centers for Medicare and Medicaid Services (CMS) for a rate reassignment that became effective 1 January 2022. These two developments represent important steps in a complex and lengthy process, but they are by no means the end of the work that needs to be done. We continue to allocate significant resources to ensure that all practices can file reimbursement claims for scalp cooling. Our business model is now evolving to align with the traditional "buy-bill" model that is familiar to U.S. medical practices, and we anticipate it will take 12-18 months to fully implement these changes.

We are pleased that the one-time cost of 9.6 MSEK that the Company made in internal Quality System improvements and Market Access efforts in 2021 is now behind us. We continue to utilize the services of select consultancy groups to help us navigate the reimbursement landscape. The investments the company made in 2021 to obtain a higher reimbursable amount for scalp cooling and to ensure our infrastructure could handle the resultant increase in business were necessary and we anticipate the returns on those investments to be significant.

As the global supply chain continues to present challenges, we are narrowing our global focus to ensure units are available firstly for our highest growth opportunity which continues to be the U.S. We will continue to move the opportunities we have in other global markets that have a high probability of meeting near term profitability and revenue goals.

Dignitana has now established a solid upward trajectory based on a superior device and our patient-first approach. As the disruptions to a normal business environment caused by the pandemic begin to recede, I have every confidence that our growth will both continue and accelerate. I am deeply appreciative of the support our shareholders and stakeholders have provided us through this difficult and unprecedented period. From the very solid foundation the company has built we continue our journey towards being a profitable and thriving organization capable of realizing the tremendous opportunities in front of us.



William Cronin, CEO
Dignitana AB



The Company

DigniCap has been on the market in Europe since 2001 and has had FDA clearance since 2015 to provide continuous scalp cooling with high efficacy, safety, and acceptable patient comfort. In 2017 Dignitana received expanded clearance from the FDA allowing DigniCap to be used by patients receiving chemotherapy to treat solid tumors from breast cancer as well as those from prostate, ovarian, uterine, lung and other tissues. In 2019 Dignitana received CE Marking and FDA clearance for sales of DigniCap Delta, the next generation scalp cooling device, followed by approvals for the new model in Australia and Israel.

Dignitana AB is a medical technology company based in Lund, Sweden and publicly traded on Nasdaq First North Growth Market in Sweden. Company headquarters are in Lund, Sweden and operations are based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Redeye AB is Certified Adviser. The Company produces the DigniCap Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy to improve well-being and quality of life. The DigniCap Scalp Cooling System was invented in 1999 by a Swedish oncology nurse.


Business model

Dignitana has two business models: in the United States devices are leased and the Company receives payments for each treatment. Outside the U.S. devices are sold to facilities and the company also receives revenue from service and maintenance agreements. The introduction of the DigniCap Delta system has added an additional revenue stream from consumables to both models with sales of the single-patient DigniCap Delta caps and patient kits.

While the pay-per-treatment model has been and continues to be the primary revenue driver for our US growth, the company is also taking significant steps towards ensuring we can seamlessly transition to the more traditional "buy/bill" model that healthcare providers utilize every day. The recent CMS rate assignment is the first step necessary for providers to finally make scalp cooling a billable service

and thus be compensated for committing the resources necessary to make scalp cooling therapy standard of care. The new "buy/bill" model will be piloted with a select group of sites starting in the first quarter of 2022. As this new model becomes more scalable and the reimbursement picture becomes clearer, we anticipate a full transition over to this standardized and widely accepted business model in the next 12-18 months.

For global markets that do not have the pay-per-treatment model, the focus is on creating a more sustainable recurring revenue stream from unit sales, lease agreements, service and maintenance fees, and sales of product disposables and supplies. The single patient, DigniCap Delta is generating additional interest from the medical community with the global trend towards greater infection control standards.



The market

The market

DigniCap minimizes chemotherapy-induced hair loss for cancer patients with solid tumors. Globally there are over 12 million incidences of solid tumors diagnosed annually, with more than 1,8 million diagnoses occurring in the U.S. each year. Dignitana estimates that 60 percent of these patients are on regimens compatible with DigniCap. Scalp cooling is primarily used today during the treatment of breast cancer, the most common type of cancer in women worldwide with over 1,7 million cases of breast cancer diagnosed annually. Scalp cooling is also used by patients with other solid tumors such as ovarian, uterine, endometrial, cervical, and prostate cancers.

To increase awareness of scalp cooling we work strategically with different organizations and interest groups in the cancer care community. Dignitana's ongoing sponsorship of Susan G. Komen, the largest breast cancer advocacy group in the world, is an example of this. In most of the world scalp cooling is not a standard option for cancer care. The acceptance, market penetration and utilization of this

treatment vary widely, providing significant opportunities for Dignitana all over the world.

Dignitana is committed to advancing the science of scalp cooling by supporting clinical trials and research initiatives among DigniCap users. The Company has initiated several studies that could expand usage to new user groups and show improvements with existing regimens that have exhibited inferior results with scalp cooling previously.

Market development

The DigniCap Scalp Cooling System is clinically proven to reduce hair loss in cancer patients undergoing chemotherapy for solid tumors. The DigniCap Scalp Cooling System has been marketed worldwide since 2009 and received FDA clearance for the US market in 2015. The DigniCap Delta model was introduced in 2019 and is a smaller, single-patient device providing optimal outcomes and improved ease of use for clinicians and patients. In 2019 DigniCap Delta received CE Marking for Europe and FDA clearance for the U.S., followed by TGA clearance for Australia.



Financial information and comments

DIGNITANA GROUP

Revenues

Group revenues are generated by direct sales of systems, leased systems, pay-per treatment fees, revenues from service and maintenance agreements, sales of individual caps and kit accessories. For the fourth quarter 2021 net sales amounted to 16 213 TSEK (12 928), an increase over the same period 2020 by 3 285 TSEK or 25 percent. YTD net sales reached 57 073 TSEK (46 629) and increase of 10 444 TSEK or 22 percent.

Dignitana operates by two business models: in the U.S. market DigniCap Delta systems are leased out and the Company gains revenues from leasing fees and payment for treatments. Outside the U.S, revenues are generated by DigniCap Delta systems being sold, frequently combined with service and maintenance agreements. In addition to this, the Company also has revenues from the sale of individual caps as well as consumables and accessories.

The U.S. market continues to be the driver in the transition to DigniCap Delta and a revised business model. At the close of the quarter there was an installed base of 386 devices.

Dignitana's revenue and costs comprise of different currencies such as USD, EUR, and SEK. Operational exchange rate effects are recognized in the income statement either under other operating income or other operating expenses depending on the net effect. In the fourth quarter 2021 net exchange effects amounted to 672 TSEK (-849) and YTD net exchange effects were 1 940 TSEK (-989). Exchange rate effects on financial holdings are recognized under other interest income and similar items and were for the fourth quarter 11 TSEK (-437), YTD 7 TSEK (-299).

Operating Expenses and Operating Result

Operating expenses increased during the quarter compared to the same period last year by 3 799 TSEK and amounted to -20 399 TSEK (-16 600) and YTD -70 482 TSEK (-62 971). During the year, the Company has made focused efforts to strengthen Quality and Regulatory Management, which together with initiatives to secure market access

have generated non-recurring costs in 2021 in the magnitude of 9.6 MSEK. In the fourth quarter 2020, the Company made a non-recurring write down of inventory, impacting Goods for Resale by 3 277 KSEK. Underlying Operating Expenses for 2021 have increased vs. 2020 as a result of expanding business activities. Travelling and marketing costs are for the year at moderate levels.

Depreciation and amortization in the Group amounted to -3 286 TSEK (-8 908), YTD -12 737 TSEK (-20 764). In the fourth quarter 2020 the Company wrote off C3 devices in the amount of -4 515 TSEK.

The operating result after depreciation for the Group was for the fourth quarter -11 417 TSEK (-19 731). Operating loss YTD amounted to -41 554 TSEK (-50 700).

Financial net

Financial net was -419 TSEK (-1 090), with corresponding YTD numbers -1 522 TSEK (-2 263) and consists mainly of interest paid on loans.

Board and Management are continuously monitoring the financial position of the Company and are of the opinion that current business plans combined with unutilized credit facilities are sufficient financial resources to cover working capital needs for the coming 12-month period.

Employees

Number of employees was at year end 25 (27) employees.

Cash Flow and Financial Position

Consolidated cash flows from operating activities during the quarter was -11 880 TSEK (-5 675), YTD -43 873 TSEK (-21 303). Cash and cash equivalents at the end of the quarter amounted to 14 501 TSEK (78 770).

CAPEX

Capex which amounted to 1 123 TSEK (3 773) in the quarter and YTD 10 556 TSEK (20 404), mainly relates to DigniCap Delta devices.

DIGNITANA PARENT COMPANY

Revenues

Total revenues the fourth quarter was 18 642 TSEK (8 672).
Other income is attributable to exchange rate effects.

Operating Expenses and Operating Result

Operating expenses increased during the quarter compared to the same period last year by 17 764 TSEK and amounted to -25 349 TSEK (-7 585).

Operating result was -10 465 TSEK (-12 478) and net result for the period was -10 455 TSEK (-13 278)

Revenue as well as expense variations between reporting periods are mainly related to timing differences of intercompany charges.



The share

Dignitana is listed on First North Growth Market since November 2011 after having been listed on Spotlight Market in Stockholm since June 2009..

Dignitana AB

TICKER	DIGN
Market Cap December 31	570 MSEK
Number of shareholders, approximately	2 675
Share price December 31	8.76
Number of shares traded during the quarter	4 595 927
Number of shares outstanding December 31	65 059 155
Registered share capital	6 505 916 SEK
Par value	0,1 SEK
Certified Adviser	Redeye

Dignitana has only one category of shares, where each share carries one vote and equal rights to the Company's assets and profits. The Company has over time issued new shares and stock option programs and in February 2020 an extraordinary general meeting was held where a decision was taken to issue a maximum of 2 500 000 employee warrants to key employees of the Company. The period for exercising the employee stock warrants will run from 1 March 2023 to 31 March 2023. The employee warrants were granted gratuitously and costs of 960 TSEK have been recognized in the 2021 closing, representing the YTD cost 2021.




In December 2020, the Board of Directors decided on a directed share issue of initially SEK 41 294 000 and an additional SEK 33 706 000 after approval by an Extraordinary General Meeting held in January 2021. Through the issue, which comprised 10 000 000 shares at a subscription price of SEK 7.50, the Company received 75 000 TSEK before issue costs.

Largest Shareholders

31 DECEMBER 2021	HOLDINGS	PERCENT
ADMA FÖRVALTNINGS AB *	16 900 000	25.98%
SWEDBANK ROBUR FONDER	5 000 000	7.69%
FÖRSÄKRINGSAKTIEBOLAGET AVANZA PENSION	4 531 785	6.97%
CBLDN-UBS FINANCIAL SERVICES INC.	4 189 739	6.44%
HANDELSBANKEN FONDER	3 000 000	4.61%
FÖRSÄKRINGSAKTIEBOLAGET SKANDIA	2 612 388	4.02%
TECHNOVOBIS AB	1 800 593	2.77%
FE SMÅBOLAG SVERIGE	1 800 000	2.77%
POURSAMAD, AMIR	1 490 095	2.29%
NORDNET PENSIONS FÖRSÄKRING AB	1 089 962	1.68%
TOTAL	42 414 562	65.19%
OTHER SHAREHOLDERS	22 644 593	34.81%
TOTAL	65 059 155	100.00%

*Change of name to Agarthia AB on 1 January 2022

Source: Euroclear



Risk factors

An investment in securities is associated with risk. Dignitana's activities are affected, and may be affected, by several factors which cannot be completely controlled by the Company. There are risks both in terms of circumstances attributable to Dignitana and those which have no specific connection with the Company.

The non-definitive list of the Company's risks pertains, but is not limited, to: Patents, key personnel, growth management, management, restructuring, development costs, competitors, dependence on individual customers, customers, authorization and registration, chemotherapy without side effects, alternative cancer treatment methods, distributors and manufacturers, profitability and future capital requirements, political risk, pandemic risks, regulatory or change of laws, disputes and currency risks.

Risks related to COVID-19

The outbreak of COVID-19 in the spring of 2020 has affected the Company's opportunities to reach customers but also customers' ability to offer scalp cooling as a form of treatment. The Company has therefore been impacted financially, although it is not possible to make a full assessment.

The Board is ultimately responsible for managing and monitoring these risks. Ongoing management is delegated to the CEO, who in turn reports to the Board.

For a detailed explanation of these risk factors view the 2020 Annual Report posted at <https://dignitana.com/investor-relations/financial-reports/>

Other information

Forward-looking statements

This report may contain statements, estimates or projections that constitute "forward-looking statements". Generally, the words "believe", "expect", "intend", "estimate", "anticipate", "project", "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the Dignitana historical experience or future projects.

Accounting principles

The consolidated financial statements comprise of Dignitana AB and its subsidiaries Dignitana Inc, and Dignitana Srl.

This interim report is prepared in accordance with Swedish GAAP, BFN 2012:1 (K3). The accounting policies remain unchanged compared with the preceding year and are the same principles that were applied for the Annual Report 2020.

Financial statements are presented in SEK, the functional currency of Dignitana AB. Assets and liabilities are translated and presented at the closing rate and the Income statement is translated and presented at period average exchange rates.

For a detailed explanation of accounting principles view the 2020 Annual Report posted at <https://dignitana.com/investor-relations/financial-reports/>

This Interim Report has not been reviewed by the Group's Auditors.

Board assurance

The Board of Directors and Chief Executive Officer declare that this Interim Report provides a fair view of the Company's operations, financial position and results, and describes material risks and uncertainties facing the Company.

Dignitana AB

Corporate Registration Number: 556730-5346

Lund, 17 February, 2022

Dignitana AB (publ) Board of Directors

Klas Arildsson
Chairman of the Board

William Cronin
Board member and CEO

Richard Dilorio
Board member

Lina Karlsson
Board member

Christian Lindgren
Board member

Ljubo Mrnjavac
Board member

Income Statement – Dignitana Group, TSEK

DIGNITANA GROUP	Q4 2021	Q4 2020	Full year 2021	Full year 2020
Operating Income				
Net sales	16 213	12 928	57 073	46 629
Other operating income	1 109	78	5 303	3 327
Total Operating Income	17 322	13 006	62 376	49 956
Operating expense				
Goods for Resale	-5 054	-7 229	-20 711	-16 921
Operating expense	-8 235	-6 559	-30 053	-29 870
Personnel expense	-8 101	-9 002	-30 386	-28 280
Depreciation and amortization of tangible and intangible assets	-3 286	-8 908	-12 737	-20 764
Other operating expenses	-4 063	-1 039	-10 043	-4 822
	-28 739	-32 737	-103 930	-100 656
Operating profit (loss)	-11 417	-19 731	-41 554	-50 700
Result from financial investments				
Other Interest income and similar items	25	-137	118	1
Interest expenses and similar items	-444	-953	-1 640	-2 264
	-419	-1 090	-1 522	-2 263
Profit after financial items	-11 836	-20 821	-43 076	-52 963
Profit before tax	-11 836	-20 821	-43 076	-52 963
Tax on profit for the period	-10	0	-10	0
Results for the Period	-11 846	-20 821	-43 086	-52 963
Average number of shares before and after dilution	65 059 155	60 565 070	65 059 155	60 565 070
Earnings per share before and after dilution, SEK	-0,18	-0,37	-0,66	-0,96

Balance Sheet – Dignitana Group, TSEK

DIGNITANA GROUP	2021-12-31 2021	2020-12-31 2020
ASSETS		
FIXED ASSETS		
Intangible assets		
Capitalized expenses for development	11 189	16 233
	11 189	16 233
Tangible assets		
Equipment, tools and installations	30 291	27 501
	30 291	27 501
Total Fixed Assets	41 480	43 734
CURRENT ASSETS		
Inventories and similar		
Finished goods and goods for resale	7 120	7 455
	7 120	7 455
Current Receivables		
Accounts Receivable	5 103	5 435
Current Tax Assets	66	61
Other Current Receivables	862	1 071
Prepaid expenses and accrued income	2 222	1 363
	8 253	7 930
Cash and Bank Balances	14 501	78 770
Total Current Assets	29 874	94 155
Total Assets	71 354	137 889
EQUITY AND LIABILITIES		
Equity		
Share Capital	6 506	6 057
Unregistered share capital	0	449
Ongoing new issue	0	33 256
Other contributed capital	222 692	189 436
Other equity including profit for the year	-198 012	-151 562
Total Equity	31 186	77 636
Provisions		
Other provisions	69	18
	69	18
Long Term Liabilities		
Other long term liabilities	15 828	1 661
Total Long Term Liabilities	15 828	1 661
Current Liabilities		
Liabilities to credit institutions	7 762	7 968
Accounts payable	6 234	13 327
Other current liabilities	761	23 737
Accrued expenses and deferred income	9 514	13 541
Total current liabilities	24 271	58 573
Total liabilities	40 099	60 235
Total Equity and Liabilities	71 354	137 889

Changes in Equity – Dignitana Group, TSEK

	Sharecapital	Other contributed capital	Retained earnings, incl. net loss for the year	Total equity
Opening equity on 1/1/2020	55 059	153 067	-153 023	55 103
New share issue	551	40 744		41 294
Ongoing new share issue	449	33 256		33 706
Reduction of share capital	-49 553		49 553	0
Issue expenses		-4 564		-4 564
Issue of warrants		189		189
Option program 2020			960	960
Net loss for the year			-52 963	-52 963
"Change in translation difference relating to subsidiaries"			3 912	3 912
Closing equity on 12/31/2020	6 506	222 692	-151 562	77 636
Net loss for the period			-43 086	-43 086
Option program 2021			960	960
"Change in translation difference relating to subsidiaries"			-4 324	-4 324
Closing equity on 12/31/2021	6 506	222 692	-198 012	31 186

Statement of Cash Flows – Dignitana Group, TSEK

DIGNITANA GROUP	Q4 2021	Q4 2020	Full year 2021	Full year 2020
Operating activities				
Profit after financial investments	-11 836	-20 821	-43 076	-52 963
Adjustments for items not affecting cash flows, etc	4 724	14 260	12 288	26 789
Tax paid	25	-52	-80	253
Cash flow from operating activities before changes in working capital	-7 087	-6 613	-30 868	-25 921
Cash flow from changes in working capital				
Change in inventories	-216	-490	-467	-1 509
Change in other current receivables	9	-1 217	422	-1 214
Change in other current liabilities	-4 586	2 645	-12 960	7 341
Cash flows from operating activities	-11 880	-5 675	-43 873	-21 303
Investing activities				
Investments in intangible assets	0	-17	0	-739
Proceeds from sale of intangible assets	0	0	0	0
Investments in tangible assets	-1 123	-3 756	-10 556	-19 665
Cash flows from investing activities	-1 123	-3 773	-10 556	-20 404
Financing activities				
New share issue	0	75 000	0	75 000
Issue expenses	0	-388	0	-170
Liabilities to credit institutions	0	0	0	189
Options issued	0	0	0	0
New loans	0	0	0	20 000
Repaid loans	0	0	-20 000	0
Changes in long and short term liabilities	7 478	-2 716	12 679	3 487
Cash flow from financial activities	7 478	71 896	-7 321	98 506
Cash flow for the period	-5 525	62 448	-61 750	56 799
Cash and cash equivalents at beginning of period				
Cash and cash equivalents at beginning of period	21 047	14 796	78 770	19 433
Exchange-rate differences in cash and cash equivalents				
Exchange-rate differences in cash and cash equivalents	-1 021	1 526	-2 519	2 538
Cash and cash equivalents at end of period	14 501	78 770	14 501	78 770

Income Statement – Dignitana AB, Parent Company, TSEK

DIGNITANA GROUP	Q4 2021	Q4 2020	Full year 2021	Full year 2020
Operating Income				
Net sales	17 690	8 561	37 743	31 324
Other operating income	952	66	1 940	3 448
Total Operating Income	18 642	8 627	39 683	34 772
Operating expense				
Goods for Resale	-524	-4 679	-7 179	-10 257
Operating expense	-21 989	-5 869	-41 512	-26 372
Personnel expense	-1 619	-805	-5 367	-2 301
Depreciation and amortization of tangible and intangible assets	-3 234	-8 841	-12 517	-20 483
Other operating expenses	-1 741	-911	-3 430	-4 510
	-29 107	-21 105	-70 005	-63 923
Operating profit (loss)	-10 465	-12 478	-30 322	-29 152
Result from financial investments				
Other Interest income and similar items	24	-137	118	0
Interest expenses and similar items	-14	-663	-473	-918
	10	-800	-355	-918
Profit after financial items	-10 455	-13 278	-30 677	-30 069
Profit before tax	-10 455	-13 278	-30 677	-30 069
Tax on profit for the period	0	0	0	0
Results for the Period	-10 455	-13 278	-30 677	-30 069

Balance Sheet – Dignitana AB, Parent Company, TSEK

DIGNITANA AB, PARENT COMPANY	2021-12-31 2021	2020-12-31 2020
ASSETS		
FIXED ASSETS		
Intangible assets		
Capitalized expenses for development	11 165	16 207
	11 165	16 207
Tangible assets		
Equipment, tools and installations	30 104	27 223
	30 104	27 223
Financial assets		
Participations in group companies	522	522
Receivable from group companies	452	409
	974	931
Total Fixed Assets	42 243	44 361
CURRENT ASSETS		
Inventories and similar		
Finished goods and goods for resale	5 289	6 143
	5 289	6 143
Current Receivables		
Accounts Receivable	1 927	1 775
Receivables from group companies	26 992	18 207
Current Tax Assets	117	61
Other Current Receivables	772	911
Prepaid expenses and accrued income	854	536
	30 662	21 490
Cash and Bank Balances	9 239	76 505
Total Current Assets	45 190	104 138
Total Assets	87 433	148 499
EQUITY AND LIABILITIES		
Equity		
Restricted equity		
Share Capital	6 506	6 057
Unregistered share capital	0	449
Fund for development expenses	11 165	15 631
	17 671	22 137
Non-restricted equity		
Share premium reserves	222 692	222 692
Other non-restricted equity	-129 442	-103 839
Results for the period	-30 677	-30 069
	62 573	88 784
Total Equity	80 244	110 921
Current Liabilities		
Accounts payable	2 124	8 620
Current payable to group company	0	0
Other current liabilities	129	20 120
Accrued expenses and deferred income	4 936	8 838
Total current liabilities	7 189	37 578
Total liabilities	7 189	37 578
Total Equity and Liabilities	87 433	148 499

Financial calendar

13 May 2022	Annual Report
19 May 2022	Q1 Report
19 May 2022	Annual General Meeting
18 August 2022	Q2 Report
17 November 2022	Q3 report
16 February 2023	2022 Year End Report

All financial reports are available at
www.dignitana.com/investor-relations/financial-reports/

Contact information

Dignitana AB

Traktorgränden 3, 226 60 Lund
+46 (0) 46-16 30 90
info@dignitana.com
investorrelations@dignitana.com
www.dignitana.se

Certified Adviser

Redeye AB
+46 8 121 576 90
certifiedadviser@redeye.se
www.redeye.se